Astellas to shrink Oklahoma payroll

The so-called "patent cliff" isn't just hurting the biggest pharma companies--or pushing them to downsize. Tokyo-based Astellas Pharma, facing the expiration of its Flomax drug patent, is offering early retirement and "voluntary termination" to its 200-strong workforce in Norman, Oklahoma. That's where Flomax is produced, and the company expects volume at that plant to fall so sharply that it won't need nearly as many workers.

The program is aimed at cutting the Norman payroll by about 30 percent, or 60 workers. Other products made there include VESIcare, a bladder-control medication, and another product solely for the Japanese market, Gaster D.

- read the story in The Oklahoman

Suggested Articles

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…

Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.